In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the ...

One of the ultimate goals of biological research is to understand the multiscale organization of the human cell and its relationship to biological function and human disease. As much of cell ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...

Bone tumor organoids are three-dimensional cell culture models derived from patient tissues or cells, capable of highly replicating the growth patterns and cell interactions of bone tumors in vitro.

A committee consisting of Dr. Codman, Dr. Ewing and Dr. Bloodgood studied a large number of cases of bone tumors, and from them they separated a group of benign giant-cell tumors. Up to that time ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib ... patients with tenosynovial giant cell tumor, a benign tumor that grows ...

The higher dosage of denosumab-bnht (Bomyntra; 120 mg/1.7 mL) is approved for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from ...

It is also used to treat hypercalcemia of malignancy that is refractory to bisphosphonate therapy and giant cell tumor of bone in adults and skeletally mature adolescents. Bomyntra ® (denosumab-bnht) ...

The FDA also approved it to treat hypercalcemia of malignancy refractory to bisphosphonate therapy and giant cell tumor of bone in adults and skeletally mature adolescents. Patients receive the ...